NEWS AND INSIGHTS FROM FINTRX
In utilizing the FINTRX family office data and research platform, which provides intel into thousands of direct deal transactions made by nearly 3,000 family offices worldwide, we explore three family offices directly investing across the life sciences space. Life sciences primarily include companies in the fields of pharmaceuticals, biotechnology, medical devices, biomedical technologies, nutraceuticals, cosmeceutical, and food processing - among others.
Founded in 2009, Arkin Holdings is a Herzliya, Israel-based single-family office managing the wealth for the Arkin family. The firm traces its roots back to 1961 when the family's patriarch Ziama Arkin founded Agis, an Israeli-based company that specialized in the import of foreign pharmaceuticals. After the death of Ziama Arkin in 1972, his son Mori continued to expand the family business, and in 1994, the group purchased its first pharmaceutical production facility. Along with this acquisition came substantial expansion into the pharmaceutical industry.
In 2005, Agis was acquired by the Irish-based pharmaceutical company Perrigo for $818M. About four years later, Mori Arkin founded Arkin Holdings to serve as his personal investment vehicle. Given the family's background in the pharmaceutical field, the firm focuses primarily on life science, biotechnology, pharmaceutical, and medical device companies. By 2020, its healthcare portfolio was valued at over $1 billion.
Today, Arkin Holdings allocates to a wide range of opportunities through four separate investment arms: Arkin Bio Ventures, Arkin Derma, Sphera, and Accelmed. The group allocates directly and via fund vehicles within the private equity, venture capital, and hedge fund spaces. In April 2016 and December 2019, Arkin Holdings directly invested in Metabomed, a drug discovery company in cancer metabolism. The private company is developing a proprietary target identification platform based on computational biology, genomics, and metabolomics. Arkin Holding regularly co-invests alongside like-minded family offices and institutional investors, when appropriate. Geographically, the firm allocates to opportunities primarily throughout Israel and the United States.
Established in 1996, Clayton Associates is a Brentwood, TN-based single family office managing the wealth of the McWhorter family, whose wealth traces back to the late Clayton McWhorter, the former founder, chairman, and CEO of HealthTrust and an integral part of the executive leadership of Hospital Corporation of America. His extensive career in healthcare ultimately led him and his sons into the venture capital space. The McWhorter family is heavily involved in philanthropy and government within Tennessee.
Today, Clayton Associates allocates to private equity, real estate, venture capital, and direct transactions. When making direct investments, the firm takes part in a range of deal stages, from early-stage venture rounds to later-stage buyouts and acquisitions. Primary sectors of interest include healthcare, technology, life sciences, media, pharmaceuticals, biotechnology, and analytics.
In April 2012, January 2016, and February 2016, Clayton Associates directly invested in KeraFAST, a Boston-based reagent company whose primary mission is to make laboratory-made research tools easily accessible to the global scientific community. Clay Associates regularly co-invests alongside other family offices, venture capital firms, and larger investors.
Founded in 2010, Bosarge Family Office - also known as Capital Technologies Inc. - is a Houston, TX-based single-family office serving as the investment vehicle for Ed Bosarge, a leader in the application of advanced mathematics in finance, energy, and medicine. The firm provides the Bosarge family with investment, administration, management, and philanthropy services.
Bosarge Family Office allocates to several investment opportunities, primarily in the areas of life sciences, venture capital, real estate, direct investments, and impact investments. Sectors of interest include renewable energy, biotechnology, therapeutics, construction, healthcare, education, and pharmaceuticals - among others.
In July 2017, the firm made two separate direct transactions in Okyanos Heart Institute, a global leader in regenerative medicine - and Diasome, a biotechnology company developing hepatocyte directed vesicle (HDV), an insulin additive, to lessen the instances of high and low blood sugar levels in people with diabetes.
FINTRX provides comprehensive intelligence on thousands of private family offices, each designed to facilitate your prospecting and capital-raising efforts. Explore in-depth profiles on each family - AUM, source of wealth, investment criteria, previous investment history, industries of interest - and other key data points to help elevate your workflow. FINTRX offers an inside look at the alternative investment industry and private capital markets.
With complete coverage of over 3,090+ family offices, 15,800+ family office contacts, and 19,600+ tracked investments, FINTRX ensures direct access to accredited investor intelligence. The FINTRX platform is an essential tool in understanding the family office landscape in the U.S. and abroad, while also empowering users to uncover commonalities with these family offices for effective, personal outreach.
To see a glimpse of the technology and how we could help streamline your prospecting processes, request a demo below.
February 08, 2021
Renae Hatcher is a member of the marketing team at FINTRX - focused on delivering targeted & relevant family office and registered investment advisor content to our subscribers.